Highlighting Unmet Needs: Real Patients, Difficult Choices

Slides:



Advertisements
Similar presentations
CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.
Advertisements

Volume 155, Issue 3, Pages (March 1996)
The PSA Era is not Over for Prostate Cancer
Prostate Cancer 2008: Challenges in Diagnosis and Management
Renal Cell Carcinoma: Prognostic Factors and Patient Selection
Prostate Cancer: Highlights from 2006
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Volume 51, Issue 4, Pages (April 2007)
Advances in the Treatment of Metastatic Prostate Cancer
Volume 53, Issue 5, Pages (May 2008)
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Volume 52, Issue 4, Pages (October 2007)
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Volume 71, Issue 1, Pages 1-3 (January 2017)
What is New in Hormone Therapy for Prostate Cancer in 2007?
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Prostate Cancer Management: What Does the Future Hold?
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Luis Martínez-Piñeiro  European Urology Supplements 
The PSA Era is not Over for Prostate Cancer
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Richard C. Harkaway  European Urology Supplements 
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Optimising Hormone Therapy in Advanced Disease
Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma  Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Jacques Irani  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Prostate Cancer 2008: Challenges in Diagnosis and Management
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Richard Berges  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Improving Flexibility and Quality of Life for Your Patients: A Must?
Bob Djavan  European Urology Supplements 
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why?  Jean-Jacques Patard 
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
Management of Prostate Cancer: Global Strategies
Treatment Options in Prostate Cancer Once Primary Therapy Fails
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Joaquim Bellmunt  European Urology Supplements 
Oncoforum Urology: Prostate Cancer 2008 at a Glance
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Guru Sonpavde, MD, Teresa G. Hayes, MD  Mayo Clinic Proceedings 
Jan Roigas  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Volume 51, Issue 5, Pages (May 2007)
Introduction European Urology Supplements
Presentation transcript:

Highlighting Unmet Needs: Real Patients, Difficult Choices Massimo Maffezzini  European Urology Supplements  Volume 8, Issue 1, Pages 4-12 (January 2009) DOI: 10.1016/j.eursup.2008.10.001 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Treatment profile of a prostate cancer patient. The changing prostate-specific antigen (PSA) profile of the patient following radical prostatectomy. A range of different androgen deprivation therapy (ADT) approaches were used sequentially in attempts to control disease with limited success. LHRH=luteinising hormone-releasing hormone; PET=positron emission tomography. European Urology Supplements 2009 8, 4-12DOI: (10.1016/j.eursup.2008.10.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Overall survival (OS) of hormone-refractory prostate cancer patients in docetaxel trials [24,43]: (a) OS in March 2007 after 867 deaths had occurred in the TAX327 population of 1006 patients randomly assigned to receive three-weekly (q3w) docetaxel, weekly (q1w) docetaxel, or mitoxantrone. (Reprinted with permission © 2008 American Society of Clinical Oncology. All rights reserved.); (b) OS after a median follow-up of 32 mo when 452 deaths had occurred in the Southwest Oncology Group (SWOG) 99-16 population of 674 patients randomly assigned to receive docetaxel plus estramustine or mitoxantrone plus prednisone. (Reprinted with permission © 2004 Massachusetts Medical Society. All rights reserved.) European Urology Supplements 2009 8, 4-12DOI: (10.1016/j.eursup.2008.10.001) Copyright © 2008 European Association of Urology Terms and Conditions